Format

Send to

Choose Destination
Paediatr Drugs. 2015 Feb;17(1):77-81. doi: 10.1007/s40272-014-0113-1.

The complexity of consenting to clinical research in phase I pediatric cancer studies.

Author information

1
Division of Haematology/Oncology, Department of Paediatrics, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada, tal.schechter-finkelstein@sickkids.ca.

Abstract

The principal aim of phase I studies is to define the recommended dosing of drugs for phase II studies through assessment of drug pharmacokinetics and observation of the drug's toxicity profile. In the setting of pediatric oncology, the use of an experimental drug in phase I study is offered when prognosis is poor. Thus, phase I oncology studies are not given to patients with a primary purpose of an intent to cure. They may offer little to no treatment benefit and carry a potential toxic effect. They may offer other benefits such as improved quality of life and relief of pain, however. Three parties are involved in the informed consent process: the parents, patients, and physicians. Families report hope as the main cause for enrollment. Physicians focus on providing information so families can decide about participation. Physicians also try to maintain hope despite understanding the nature of the disease. This makes the informed consent complicated for all parties involved in the process. The purpose of this review is to discuss the aims of phase I studies in pediatric oncology and to convey the ethical challenges that patients, parents, and physicians are facing when discussing informed consent with potential study participants.

PMID:
25573671
DOI:
10.1007/s40272-014-0113-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center